Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Italfarmaco SPA

www.italfarmaco.it

Latest From Italfarmaco SPA

Italfarmaco Options Inhaled Teicoplanin For MRSA Lung Infections

Italfarmaco and Neupharma plan to collaborate on the development of a new inhaled formulation of a Gram-positive targeted antibiotic for MRSA infections in cystic fibrosis.

 

Deals Infectious Diseases

Cytokinetics Sees Enough Evidence To Move Reldesemtiv Into Phase III For ALS

The Astellas-partnered drug did not reach statistical significance on any FORTITUDE-ALS endpoints, but clinically significant results over time justify a longer Phase III study that's likely to enroll ALS patients with a faster rate of disease progression.

Clinical Trials Neurology

ITF Pharma Plans October US Roll-Out Of Liquid Riluzole Formulation For ALS

Early engagement with US payers suggests openness to covering a liquid form of riluzole, because the tablet version is proven, but it's impossible to take for many ALS patients, says Italfarmaco subsidiary ITF Pharma.

Rare Diseases Approvals

Duchenne Muscular Dystrophy: The Race For The $1bn Opportunity

With three products now approved in Europe and/or the US for Duchenne Muscular Dystrophy, an FDA decision pending on PCT Therapeutics' ataluren and multiple companies exploring different approaches in preclinical and clinical studies, Scrip provides an overview of the development landscape and commercial results to date.

Rare Diseases Innovation
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Italy
  • Company Type
  • Midsize European
  • Parent & Subsidiaries
  • Italfarmaco SPA
  • Senior Management
  • Barallobre Carlos, CEO
    Francesco De Santis, Pres.
  • Contact Info
  • Italfarmaco SPA
    Phone: (39) 02 64431
    V.le Fulvio Testi, 330
    Milan, 20126
    Italy
Advertisement
Advertisement
UsernamePublicRestriction

Register